Extraction, Purification and Amplification of the Hemagglutinin Gene from Influenza Virus Type B Infected Blood and Use of this Protein in Vaccine Designing

Abstract

The epidemic caused by an influenza B virus (IBV), had a huge impact around the world. Since a hemagglutinin (HA) genes are among the most specific genes in the influenza virus genome, Antigenic kits can be definitively diagnosed by viral gene analysis targeting the (HA) genes. This analysis, however, cannot be easily performed in a clinical setting. Require the effectiveness of current influenza vaccines and The presence of antigenic close relationship between the vaccine and circulating strains. As such, the determination of antigenic variants of influenza virus emerging "In a hasty fashion" with "hastily", is essential for the success of influenza vaccine. The hemagglutinin protein of (IBV) is high foresight, it is said to play a distinguished role in the creation of pathogencity. The DNA of (IBV) was isolated from infected human blood samples. This primer was specially developed for Gene HA. The hemagglutinin gene sequence is amplified using (PCR) method and sequenced. It was expanded to work on the development of a vaccine peptide vaccine using the reverse Vaccinology method of Bioinformatics. The antigenicity study, surface accessibility area (SAA) calculation are the steps required for deciding the best antigenic peptides. Experimental procedure’s to define (IBV) antigenic properties take a long time and require live viruses. Here, we present a vision, experimentally supported, a calculation mode for determining (IBV) antigenicity on the basis of (HA) sequence. This method integrates a bootstrapped ridge regression with antigenic peptides were designed and protein structure prediction was done.